Decipher Biosciences, Inc. (DECI)
| Market Cap | n/a |
| Revenue (ttm) | 33.26M |
| Net Income (ttm) | n/a |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About DECI
Decipher Biosciences is a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers. Our novel prostate cancer genomic testing products, Decipher Biopsy and Decipher RP, provide valuable information about the underlying biology of a patient’s tumor, assisting physicians in their selection of an optimal therapy. Our differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis,... [Read more...]
Financial Performance
In 2019, DECI's revenue was $16.52 million, an increase of 36.89% compared to the previous year's $12.07 million. Losses were -$18.45 million, -38.37% less than in 2018.
Financial StatementsNews
Genomics testing provider Decipher Biosciences files for a $100 million IPO
Decipher Biosciences, which provides genomic testing products for urologic oncology, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Decipher Biosciences IPO Registration Document (S-1)
Decipher Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.